47 citations
,
April 2020 in “Dermatologic Therapy” Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.
30 citations
,
October 2020 in “Nature Communications” Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.
15 citations
,
August 2021 in “Reviews in endocrine and metabolic disorders” COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.
5 citations
,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
4 citations
,
May 2021 in “Journal of The European Academy of Dermatology and Venereology” Hair loss doesn't affect COVID-19 severity.
3 citations
,
December 2021 in “Physiological Research” Low testosterone may increase COVID-19 severity in men.
1 citations
,
April 2021 in “International Journal of Dermatology” Women with conditions like PCOS may have a higher risk of COVID-19, but treatments like isotretinoin could help those with acne.
April 2026 in “Signal Transduction and Targeted Therapy” Balancing testosterone may reduce COVID-19 severity.
June 2020 in “Journal of Dermatological Treatment” Use telemedicine and strict hygiene for safe hair and scalp treatments during COVID-19.
19 citations
,
March 2017 in “Scientific Reports” HAT-L4 is crucial for preventing body fluid loss by maintaining skin barrier integrity.
402 citations
,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
185 citations
,
August 2020 in “Mayo Clinic Proceedings” Men are more likely to have severe COVID-19 cases and fatalities than women due to factors like lifestyle, aging, and biological differences.
113 citations
,
July 2020 in “Communications biology” Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
70 citations
,
July 2020 in “Pharmacological Reports” Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
68 citations
,
May 2021 in “Endocrine” People with diabetes or obesity should manage their conditions carefully as they have a higher risk of severe COVID-19.
56 citations
,
February 2006 in “American journal of physiology. Cell physiology” Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.
49 citations
,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
47 citations
,
January 2021 in “Fertility and Sterility” COVID-19 might affect male fertility, but more research is needed to understand the full impact.
26 citations
,
September 2020 in “Journal of the European Academy of Dermatology and Venereology” A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
25 citations
,
January 2022 in “Endocrine journal” Long COVID patients may have hormonal imbalances linked to their symptoms.
21 citations
,
January 2021 in “Journal of infection and chemotherapy” Men, diabetes, and high inflammation levels lead to higher COVID-19 antibodies.
11 citations
,
May 2021 in “Journal of Medical Virology” Men are more likely to have severe respiratory viral infections like COVID-19 due to hormonal and genetic differences, while women generally have stronger immune responses.
6 citations
,
December 2020 in “Dermatological reviews” COVID-19 may worsen with androgens; anti-androgen drugs could help.
5 citations
,
July 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.
March 2025 in “MAEDICA – a Journal of Clinical Medicine” COVID-19 may worsen symptoms of benign prostatic hyperplasia (BPH).
December 2022 in “Urology Herald” Hormonal status from androgen deprivation therapy may affect COVID-19 severity in men.
January 2022 in “Asian journal of Current Research in Clinical Cancer” Some dibenzo compounds might help treat cancer with fewer side effects.
Cepharanthine and tetrandrine show promise as COVID-19 drugs.
September 2020 in “arXiv (Cornell University)” Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.
30 citations
,
October 2010 in “Journal of The American Academy of Dermatology” The conclusion suggests a possible link between iron levels and hair health in women, recommending further research on iron supplementation for hair loss.